NEW YORK (GenomeWeb) – Pathology Associates Medical Laboratories (PAML) today announced that it has entered into a collaboration with Axela to develop multiplex assays to detect patient immunity to diseases that can be prevented with vaccines.

The serologic assays will measure antibodies to a wide range of viruses including measles, mumps, and rubella to help determine a patient's immunity to those diseases. The terms of the agreement also call for multiplex targets beyond the initial serological assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.